Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients

Hematology/ Oncology and Stem Cell Therapy

Volumn 5, Issue 1, 2012, Pages 54-59

  Mansour, Ahmed Kamel ^a   Aly, Rabab Mahfouz ^a   Abdelrazek, Sohier Yahia ^a   Elghannam, Doaa Mahmoud ^a   Abdelaziz, Sherin Mohamed ^a   Shahine, Dina Abdalhalim ^b   Elmenshawy, Nadia Mohamed ^a   Darwish, Ahmad Mohamad ^a  

^a Department of Pediatrics ^*  (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGING; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; INFANT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD;

EID: 84859016400     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2012.54     Document Type: Article

References (34)

1. Amal El-Beshlawy and Ilham Youssry. Prevention of Hemoglobinopathies in Egypt. Hemoglobin. 2009;33 Suppl 1:S14-20.
2. Alavian SM. Hepatitis C infection inIran; A review article. Iran J Clin Infect Dis 2009;4:47-59.
3. Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003;9:S10-3. [14586889][doi:10.1053/jlts.2003.50244]
4. Alavian SM. Ministry of Health in Iran is serious about controlling hepatitis B. Hepatitis Monthly 2007;7(1):3?5.
5. Attia MA. Prevalence of hepatitis B and C in Egypt and Africa. Antivir Ther 1998;3:1-9.
6. El-Zayadi A. Hepatitis B Virus Infection the Egyptian Situation. Arab J Gastroenterol 2007;8:94-98.
7. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med 2005;8:84-90.
8. Agarwal MB, Malkan GH, Bhave AA, Vishwanathan C, Billa V, Dube SR, et al. Antibody to hepatitis-C virus in multi-transfused thalassaemics--Indian experience. J Assoc Physicians India. 1993;41(4):195-197.
9. Di Marco V, Capra M, Angelucci E, Borgna- Pignatti C, Telfer P, Harmatz P et al. Management of chronic viral hepatitis in patients with thalas- semia: recommendations from an international panel. Blood 2010;116:2875-2883.
10. Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology 0f HCV infection among Thalassemia patients in eastern Mediterranean countries: a quantitative review of literature. IRCMJ 2010;12:365-76.
11. Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassemia major. Vox-Sang 2000;79(3):129-137.
12. Shah N, Mishra A, Chauhan D, Vora CShah NR. Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in western India. Asian J ofv transfusion science. 2010;4: 94-98.
13. Al Shayyab M, Baticha A, El Khateeb M. The prevalence of hepatitis B, hepatitis C and human immunodeficiency virus markers in multi-transfusion patients. J Trop. Pediatr. 2001;47(4):239-242.
14. Jaiswal SP, Chitnis DS, Jain AK, Inamdar S, Porwal A, Jain SC. Prevalence of hepatitis viruses among multi-transfused homogenous thalassaemia patients. Hepatol Res. 2001;26;19(3):247-253.
15. Khakhkhar V, Joshi PJ. HBsAg seropositivity among multi-transfused thalassemic children. Indian J Pathol Microbiol 2006;49(4):516-518.
16. Singh H, Pradhan M, Singh RL, Phadeke S, Naik SR, Aggarwal R, Naik S. High frequency of hepatitis B virus infection in patients with?-thalassemia receiving multiple transfusions.Vox sanguinis 2003;84:292-299.
17. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, Zand V, Azami AA, Hosseini MM, Faridi AR, Davari K, Hajibeigi B. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006; 9: 319-23.
18. Shah SMA, khan MT,Zahour Ullah and Ashfaq NY. Prevalence of Hepatitis B and Hepatitis C virus infection in multi-transfused thalassemia major patients in North West Frontier Province, Pak J Med Sci 2005;21(3):281-283.
19. Ocak S, Kaya H, Cetin M, Gali Ozturk M. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a longterm follow-up. Arch Med Res 2006;37(7):895-898.
20. Ramia S, Koussa S, Taher A, et al. Hepatitis- Cvirus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. Ann Trop Med Parasitol 2002;96(2):197-202.
21. Gerety RJ, Aronson DL. Plasma derivatives and viral hepatitis, transfusion, 2003, 22(5):347-351.
22. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engel J Med 1992; 327:369-373.
23. Di MV, Lo IO, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in betathalassemics with chronic hepatitis C. Blood 1997; 90:2207-2212.
24. Jamal R, Fadzillah G, Zulkifli SZ, Yasmin M. Seroprevalence of hepatitis B, hepatitis C, CMV and HIV in multiply transfused thalassaemia patients: results from a thalassaemia day care centerin Malaysia. Eur J Clin Microbiol Infect Dis 1999;18: 709-715.
25. Bhatti FA, Amin M, Saleem M. Prevalence of antibody to hepatitis C virus in Pakistani thalassaemics by particle agglutination test utilizing C 200 and C 22-3 viral antigen coated particles. J Pak Med Assoc 1995;45(10):269-271
26. Prati D, Zanella A, Farma E, et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood 1998;92(9):3460-3464
27. Parti D, Zanella A, Farma E, Mattei CD, Bosoni P. A multicentre prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta thalassaemia. Blood 1998;9:3460-3464.
28. Ni YH, Chang MH, Lin KH et al.Hepatitis C viral infection in thalassemic children: clinical and molecular studies. Pediatr Res 1996;39(2):323-328.
29. Cacopardo B, Russo R, Fatuzzo F, Cosentino S, La Rosa R,. Celesia BM, Nigro L, Nunnari A, Lombardo T and Frontini V. HCV and HBV infection among multitransfused thalassemics from Eastern Sicily. Infection 1992;20(2):83-85.
30. Al-Fuzae L, Aboolbacker KC, Al-Saleh Q. Beta-thalassemia major in Kuwait. J Trop Pediatr 1998;44: 311-312.
31. Al-Mahroos FT, Ebrahim A. Prevalence of hepatitis B, hepatitis C, and human immune deficiency virus markers among patients with hereditary hemolytic anaemias. Ann Trop Paediatr 1995;15:121-128.
32. Laosombat V, Pornpatkul M, Wongchanchailert M, Worachat K, Wiriyasatienku A. The prevalence of hepatitis C virus in thalassaemic patients in the south of Thailand. Southeast Asia J Trop Med Public Health 1997;28:149-153.
33. Mele A, Stroffolini T, Catapano R, Palumbo F, Moiraghi A, Novaco F. Incidence of transfusionassociated B and non-A, and non-B hepatitis in Italy.Br Med J 1995;311:846-847.
34. Hussain H, Iqbal R, Khan MH, Iftikhar B, Aziz S, Burki FK, sethi J and Hassan M. Prevalence of hepatitis C in Beta tahalssemia major. Gomal Journal of Medical Sciences July-December 2008, Vol. 6, No. 2.